Cancer Res Treat.  2022 Apr;54(2):488-496. 10.4143/crt.2021.394.

A Real-world Efficacy of Nab-paclitaxel Monotherapy in Metastatic Breast Cancer

• Kim JS
• Suh KJ
• Lee DW
• Woo Gu
• Kim M
• Kim SH
• Ryu HS
• Lee KH
• Kim TY
• Han SW
• Park SY
• Park IA
• Kim JH
• Im SA

• KMID: 2528218
• DOI: http://doi.org/10.4143/crt.2021.394

Abstract

Purpose
We aimed to assess the real-world efficacy of nab-paclitaxel in metastatic breast cancer patients.
Materials and Methods
This is a retrospective study performed in two tertiary referral hospitals in Korea. Patients with metastatic breast cancer treated with nab-paclitaxel (Abraxane®) between March 2016 and March 2020 were enrolled.
Results
A total of 102 patients with metastatic breast cancer were included. Patients were heavily pre-treated with a median of four prior lines of chemotherapy (5 lines when including endocrine therapy in hormone-receptor-positive patients), and 66 patients (64.7%) were exposed to taxanes in the metastatic setting. According to St. Gallen molecular subtypes, 36 patients (35.3%) were luminal A, 28 (27.5%) were luminal B, 18 (17.7%) were human epidermal growth factor receptor 2–positive and 20 (19.6%) had triple-negative disease. Fifty patients (49.0%) were treated with a 3-weekly regimen (260 mg/m² on day 1 every 3 weeks), and 52 (51.0%) were treated with a weekly regimen (100 mg/m² every week). Objective response rate was 22.9%. After a median follow-up of 22.0 months, median progression-free survival (PFS) was 4.0 months (95% confidence interval [CI], 2.6 to 4.8) and median overall survival was 8.7 months (95% CI, 7.5 to 11.2). Patients treated with weekly regimen had longer PFS compared to 3-weekly regimen (5.5 vs. 2.3 months, p < 0.001). Multivariate analysis revealed the treatment regimen as an independent prognostic factor for PFS. There was no grade 3 or 4 hypersensitivity reaction.
Conclusion
This real-world data shows that nab-paclitaxel is a reasonable treatment option in heavily pre-treated and/or taxane-exposed metastatic breast cancer patients.

Keyword

Albumin-bound paclitaxel; Breast neoplasms; Neoplasm metastasis

Figure

• 

  Fig. 1 Kaplan-Meier curves of progression-free survival (PFS, A) and overall survival (OS, B) in metastatic breast cancer treated with nab-paclitaxel. CI, confidence interval.

• 

  Fig. 2 Kaplan-Meier curves of progression-free survival (PFS, A) and overall survival (OS, B) by dosing schedule of nab-paclitaxel. CI, confidence interval.

Reference

References

1. McGrogan BT, Gilmartin B, Carney DN, McCann A. Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta. 2008; 1785:96–132.

2. ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet. 2003; 42:665–85.

3. Gradishar WJ, Krasnojon D, Cheporov S, Makhson AN, Manikhas GM, Clawson A, et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol. 2009; 27:3611–9.

4. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005; 23:7794–803.

5. Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018; 379:2108–21.

6. Ricciuti B, Dahlberg SE, Adeni A, Sholl LM, Nishino M, Awad MM. Immune checkpoint inhibitor outcomes for patients with non-small-cell lng cancer receiving baseline corticosteroids for palliative versus nonpalliative indications. J Clin Oncol. 2019; 37:1927–34.

7. Scott SC, Pennell NA. Early use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab. J Thorac Oncol. 2018; 13:1771–5.

8. Ibrahim NK, Samuels B, Page R, Doval D, Patel KM, Rao SC, et al. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol. 2005; 23:6019–26.

9. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010; 28:2784–95.

10. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013; 31:3997–4013.

11. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ, et al. Strategies for subtypes: dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011; 22:1736–47.

12. Desai N. Nanoparticle albumin-bound paclitaxel (Abraxane). Otagiri M, Chuang VT, editors. Albumin in medicine: pathological and clinical applications. Singapore: Springer;2016. p. 101–19.

13. Fang J, Sawa T, Maeda H. Factors and mechanism of “EPR” effect and the enhanced antitumor effects of macromolecular drugs including SMANCS. Adv Exp Med Biol. 2003; 519:29–49.

14. Yamamoto Y, Kawano I, Iwase H. Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval. Onco Targets Ther. 2011; 4:123–36.

15. Martin M. nab-Paclitaxel dose and schedule in breast cancer. Breast Cancer Res. 2015; 17:81.

16. National Comprehensive Cancer Network. Breast cancer (version 6.2020) [Internet]. Plymouth Meeting, PA: National Comprehensive Cancer Network;2020. [cited 2021 Aug 1]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf .

17. Blum JL, Savin MA, Edelman G, Pippen JE, Robert NJ, Geister BV, et al. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer. 2007; 7:850–6.

18. Miles D, Gilgorov J, Andre F, Cameron D, Schneeweiss A, Barrios CH, et al. Primary results from IMpassion131, a double-blind placebo-controlled randomized phase III trial of first-line paclitaxel (PAC)±atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC). Ann Oncol. 2020; 31(Suppl 4):S1142–215.

19. Soliman HH. nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors. Onco Targets Ther. 2017; 10:101–12.

20. Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol. 2008; 26:1642–9.

21. Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008; 358:1663–71.

22. Marschner N, Salat C, Soling U, Hansen R, Grebhardt S, Harde J, et al. Final effectiveness and safety results of NABUCCO: real-world data from a noninterventional, prospective, multicenter study in 697 patients with metastatic breast cancer treated with nab-paclitaxel. Clin Breast Cancer. 2018; 18:e1323–37.

23. Jackisch C, Luck HJ, Untch M, Bischoff J, Muller V, Schmidt M, et al. Weekly nab-paclitaxel in metastatic breast cancer: summary and results of an expert panel discussion. Breast Care (Basel). 2012; 7:137–43.